SPC waiver
Pharma Brexit Brief Quick Facts

Pharma Brexit Brief

What is Pharma Brexit Brief? It is a living source of updated brief key points to watch for the pharmaceutical industry on Brexit, “deal” or “no-deal” resolution. Pharma Brexit Brief is a single source of information to refer to. Brexit´s Key Impact Aspects on Pharmaceutical Industry: Labor: UK is the third largest country in the EU (after Germany and Switzerland) to utilize pharmaceutical R&D funds of pharmaceut
Read More

The new SPC waiver impact on the biosimilars market in Europe

On February 26, 2019, the Committee on Legal Affairs of the European Parliament approved the draft text of the regulation on a supplementary protection certificate SPC waiver. Earlier this year, the Legal Committee of the European Parliament (JURI) has voted in favor of the SPC manufacturing waiver. Read the full article on LinkedIn. With the introduction of SPC waiver for export and stockpiling, generic and biosimil
Read More